Health November 12, 2026

Pharmacy compounding meets infection prevention: 5 collaboration opportunities for cleanroom safety

Key Takeaways

  • Early collaboration between pharmacy and infection prevention teams strengthens cleanroom design and contamination control from day one.
  • Infection preventionists' objective coaching on hand hygiene and aseptic technique helps pharmacy teams catch risks internal staff may overlook.
  • Shifting conversations from compliance to actual patient risk turns environmental monitoring results into a powerful, collaborative safety tool.
Two of Wolters Kluwer’s in-house clinical experts teamed up for a webinar exploring the intersection between pharmacy compounding and infection control standards. Here are five takeaways for creating a safer, more compliant cleanroom environment.

Healthcare organizations invest significant resources in maintaining sterile compounding environments, yet one of the most underutilized strategies for reducing contamination risk may already exist within their walls: stronger collaboration between pharmacy and infection prevention.

Historically, sterile compounding and infection prevention and control (IPC) teams have operated in silos. Pharmacy teams focus on compliance with USP standards, aseptic technique, environmental controls, and medication preparation, while infection preventionists (IPs) promote a culture of safety for patients and staff. IPs perform surveillance to identify healthcare-associated infections, lead process improvement, guide outbreak response, and promote evidence-based safety policies and practices. Although their daily responsibilities differ, both groups share a common objective—protecting patients from preventable harm.

As healthcare regulations evolve and compounding environments become increasingly complex, organizations have an opportunity to bridge these disciplines in ways that improve risk assessment, strengthen compliance efforts, and enhance patient safety. To address this gap, Karen Jones and Christina Martin hosted a webinar on strengthening partnerships between your pharmacy compounding and infection prevention teams. The discussion revealed five important opportunities to enhance cleanroom safety.

Different perspectives, a shared approach to safer sterile compounding

The revised USP <797> chapter effective November 1, 2023, places significant emphasis on personnel competency, environmental monitoring, cleaning and disinfection programs, facility design, and ongoing quality management. Yet many of these activities also fall within the expertise of infection prevention programs.

Pharmacy professionals are experts in compounding operations, product preparation, workflow design, and USP compliance. Infection preventionists bring a different lens—evaluating infection risks, interpreting microbiological trends, conducting investigations, and developing mitigation strategies.

When those perspectives are combined, organizations gain a more comprehensive approach to cleanroom safety.

1. Identify infection control standards for sterile compounding early in cleanroom design and renovation

Few decisions have a greater long-term impact on contamination control than facility design.

Whether constructing a new cleanroom suite, renovating existing sterile compounding space, or addressing infrastructure concerns, pharmacy and infection prevention should be involved from the earliest planning stages. Pharmacy professionals understand operational workflows and compounding requirements, while infection preventionists bring expertise in environmental controls and infection risk mitigation.

Construction projects also introduce new contamination risks. IPs routinely use Infection Control Risk Assessments (ICRAs) to evaluate risks associated with construction activities and determine appropriate containment strategies. Early collaboration helps organizations identify vulnerabilities before they impact operations.

The most successful projects don't simply meet engineering specifications but also incorporate designs with contamination prevention in mind from day one.

2. Partner on training, hand hygiene, and aseptic practices

People remain the greatest source of contamination within controlled environments.

USP <797> emphasizes hand hygiene, garbing, competency assessments, and aseptic technique for anyone entering sterile compounding spaces. Any person who enters the cleanroom-controlled environment setting, including pharmacy personnel, maintenance staff, contractors, auditors, and visitors, all contribute to potential contamination risk. This creates a valuable opportunity for IPs to support pharmacy training programs.

Organizations that engage IPC teams in competency evaluations, observation audits, and remediation efforts may uncover opportunities for improvement that internal teams overlook. An external observer often identifies workflow deviations, hand hygiene lapses, or garbing inconsistencies that can become normalized over time.

Because IPs routinely evaluate healthcare personnel compliance across clinical environments, they can provide practical coaching and objective feedback that strengthens sterile compounding practices.

3. Move beyond compliance and focus on infection risk

USP standards establish minimum requirements. However, not every compliance deviation carries the same clinical risk.

One of the most valuable contributions IPs can make is helping pharmacy teams interpret findings through a patient-safety lens. While USP <797> describes monitoring frequencies, action levels, and operational requirements, it may not always provide detailed guidance on the true infection risk associated with specific contamination events.

For example, environmental monitoring programs frequently detect microorganisms that require investigation. Pharmacy teams may accurately identify a recovery event, yet questions often remain, such as:

  • Is the organism clinically significant?
  • Has it been recovered elsewhere in the facility?
  • Does it pose an elevated risk to immunocompromised patients?
  • Does the finding warrant enhanced surveillance or operational restrictions?

These questions extend beyond USP compliance and often benefit from IPC team expertise.

Organizations that shift discussions from "Are we compliant?" to "What is the actual patient risk?" create more meaningful and effective responses to contamination concerns.

4. Use environmental monitoring results as a collaborative tool

Environmental monitoring frequently serves as the intersection between pharmacy and IPC.

USP <797> establishes minimum expectations for air and surface sampling, but successful contamination investigations often require broader interdisciplinary review. Environmental conditions, seasonal changes, facility issues, personnel practices, and microbiological trends can all influence monitoring results.

In one case discussed during the webinar, repeated recoveries of Sphingomonas near an anteroom sink prompted a multidisciplinary investigation involving pharmacy leadership, microbiology, infection prevention, and facilities management. The team examined historical recovery trends, facility conditions, personnel changes, cleaning practices, and environmental factors before developing corrective actions and monitoring plans.

No single department possessed all the answers. The solution emerged through collaboration.

Environmental monitoring data should not simply trigger corrective actions; it should also spark conversation among subject matter experts who can collectively determine the most appropriate response.

5. Establish clear plans for cleanroom emergencies

Some collaboration opportunities are planned, while others arise unexpectedly. The organizations that respond most effectively have already established communication pathways before an event occurs.

Water intrusions, HVAC failures, pressure differential excursions, environmental monitoring action-level recoveries, and unusual infection clusters all require rapid, coordinated responses. IPs are particularly skilled at incident assessment, outbreak investigations, risk evaluations, and mitigation planning.

When a contamination event occurs, teams should not be meeting one another for the first time. Joint participation in quality meetings, routine reporting reviews, risk assessments, policy development, and regulatory preparedness activities proactively create productive relationships that become invaluable before high-pressure situations arise.

The importance of infection control standards for sterile compounding: A lesson reinforced by history

The importance of interdisciplinary collaboration became painfully evident during the 2012 New England Compounding Center fungal meningitis outbreak linked to contaminated compounded sterile preparations. The event resulted in hundreds of infections and dozens of patient deaths, ultimately leading to increased oversight and regulatory reforms around sterile compounding. Investigations identified significant sterile compounding failures that demonstrated the consequences of inadequate contamination controls.

While healthcare organizations have made tremendous progress since 2012, the underlying lesson remains relevant: contamination prevention requires more than compliance alone. It requires vigilance, expertise, communication, and partnership.

A collaborative path forward for compounding safety

If your pharmacy and IPC teams interact only when an issue occurs, there may be an opportunity to strengthen that relationship.

Start with a cleanroom tour. Invite IPs to quality meetings. Share environmental monitoring trends. Review policies together. Participate jointly in investigations and survey readiness tools.

The goal is not to create additional work. The goal is to leverage complementary expertise in ways that improve decision-making and strengthen patient protection. When pharmacy compounding and IPs work together, everyone benefits, but most importantly, so do the patients who depend on the medications prepared in those cleanroom environments.

Learn About Sentri7® Clinical Surveillance and Simplifi+® Compliance Solutions 

References:

  1. Smith, R. M., Schaefer, M. K., Kainer, M. A., et al. (2013). Fungal infections associated with contaminated methylprednisolone injections. New England Journal of Medicine.
  2. Jones, K. (2025, October 3). Stop the spread: How infection preventionists can combat infodemics. Wolters Kluwer Expert Insights.
  3. Ormsby, J., & Ashley, A. L. (2023, August). Ten key points the infection preventionist needs to know about USP <797>: Pharmaceutical compounding—sterile preparations. Association for Professionals in Infection Control and Epidemiology (APIC) Practice Guideline.
  4. Association for Professionals in Infection Control and Epidemiology. (n.d.). Toolkits, guides and briefs. APIC.
Back To Top